Literature DB >> 6311904

The mechanism of retrovirus suppression of human T cell proliferation in vitro.

E A Copelan, J J Rinehart, M Lewis, L Mathes, R Olsen, A Sagone.   

Abstract

Immunosuppression is commonly associated with retrovirus-induced animal tumors. Studies in the murine and feline retrovirus systems suggest that the 15,000-dalton envelope protein (p15E) of the virion may contribute to immunosuppression by interfering with normal lymphocyte function. We examined the effect of inactivated feline leukemia virus (UV-FeLV) and p15E derived from this virus on concanavalin A (Con A) driven human T cell proliferation. Virus and p15E markedly suppressed mononuclear cell proliferative response to Con A. Suppression was not due to inhibition of monocyte accessory cell function, or interleukin 1 (IL 1) secretion. In fact, the presence of monocytes partially protected T cells from UV-FeLV suppression. UV-FeLV, however, suppressed T cell secretion of and response to interleukin 2 (IL 2). We conclude that UV-FeLV and derived p15E inhibit T cell proliferation by direct inhibition of T cell function. These findings, extended to the in vivo situations, suggest that retrovirus-associated suppression of the immune response involves the induction of T cell but not monocyte dysfunction.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6311904

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  29 in total

Review 1.  Feline leukemia virus: current status of the feline induced immune depression and immunoprevention.

Authors:  R G Olsen; M G Lewis; L J Lafrado; L E Mathes; K Haffer; R Sharpee
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

Review 2.  Antiviral therapy in AIDS. Clinical pharmacological properties and therapeutic experience to date.

Authors:  E G Sandström; J C Kaplan
Journal:  Drugs       Date:  1987-09       Impact factor: 9.546

3.  Effect of Friend leukemia virus infection on susceptibility to Candida albicans.

Authors:  M A Moors; S M Jones; K K Klyczek; T J Rogers; H R Buckley; K J Blank
Journal:  Infect Immun       Date:  1990-06       Impact factor: 3.441

Review 4.  Mechanisms of virus-induced immune suppression.

Authors:  M A Wainberg; E L Mills
Journal:  Can Med Assoc J       Date:  1985-06-01       Impact factor: 8.262

5.  Identification, using synthetic peptides, of the minimum amino acid sequence from the retroviral transmembrane protein p15E required for inhibition of lymphoproliferation and its similarity to gp21 of human T-lymphotropic virus types I and II.

Authors:  C L Ruegg; C R Monell; M Strand
Journal:  J Virol       Date:  1989-08       Impact factor: 5.103

6.  Reversible interference with TCGF activity by virus particles.

Authors:  M A Wainberg; S Vydelingum; M Boushira; J Legacé-Simard; R G Margolese; B Spira; J Mendelson
Journal:  Clin Exp Immunol       Date:  1984-09       Impact factor: 4.330

7.  Abnormal monocyte chemotaxis in patients with chronic purulent rhinosinusitis: an effect of retroviral p15E-related factors in serum.

Authors:  E M van de Plassche-Boers; M Tas; M de Haan-Meulman; M Kleingeld; H A Drexhage
Journal:  Clin Exp Immunol       Date:  1988-09       Impact factor: 4.330

8.  Successful tumour immunotherapy: possible role of antibodies to anti-inflammatory factors produced by neoplasms.

Authors:  M Nelson; D S Nelson; P B Spradbrow; V K Kuchroo; P A Jennings; G J Cianciolo; R Snyderman
Journal:  Clin Exp Immunol       Date:  1985-07       Impact factor: 4.330

Review 9.  Endogenous env elements: partners in generation of pathogenic feline leukemia viruses.

Authors:  P Roy-Burman
Journal:  Virus Genes       Date:  1995       Impact factor: 2.332

10.  A targeted mutation within the feline leukemia virus (FeLV) envelope protein immunosuppressive domain to improve a canarypox virus-vectored FeLV vaccine.

Authors:  Géraldine Schlecht-Louf; Marianne Mangeney; Hanane El-Garch; Valérie Lacombe; Hervé Poulet; Thierry Heidmann
Journal:  J Virol       Date:  2013-11-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.